Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood (2022) 140 (Supplement 1): 10137–10139.

https://doi.org/10.1182/blood-2022-158146

Published: 2022

Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood (2022) 140 (Supplement 1): 397–399.

https://doi.org/10.1182/blood-2022-157988

Published: 2022

Journal Articles

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Domenico Galati, MD PhD, Davide Coppola, RN, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Francesco Volzone, MD, Emanuela Morelli, MD, Daniela Donnarumma, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Niels Odum, MD, Thomas Mehrling, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 2547.

https://doi.org/10.1182/blood.V130.Suppl_1.2547.2547

Published: 2017

Journal Articles

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Michele Cillo, ScD, Sara Mele, BS, Angela De Monaco, ScD, Domenico Galati, MD, Serena Zanotta, ScD, Gaetana Capobianco, MD, Francesco Volzone, MD, Manuela Arcamone, MD, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD PhD, Thomas Mehrling, MD PhD, Antonello Pinto, MD

Blood (2015) 126 (23): 2481.

https://doi.org/10.1182/blood.V126.23.2481.2481

Published: 2015

Journal Articles

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Ferdinando Frigeri, MD, PhD, Raffaele Di Francia, PhD, Luigi Petraccone, PhD, Concetta Giancola, PhD, Annunziata Cummaro, PhD, Paolo Danise, MD, Stefania Crisci, PhD, Giancarla Iaccarino, PhD, Rosaria De Filippi, MD, PhD, Emanuela Morelli, MD, Gaetana Capobianco, MD, Francesco Volzone, MD, Alfonso Maria D'Arco, MD, Antonio Pinto, MD

Blood (2011) 118 (21): 5168.

https://doi.org/10.1182/blood.V118.21.5168.5168

Published: 2011

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Emanuela Morelli, MD, Francesco Volzone, MD, Filippo Russo, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2829.

https://doi.org/10.1182/blood.V116.21.2829.2829

Published: 2010

Journal Articles

Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph + acute lymphoblastic leukemia during long-term imatinib mesylate treatment

Giovanni Riva, Mario Luppi, Patrizia Barozzi, Chiara Quadrelli, Sabrina Basso, Daniela Vallerini, Eleonora Zanetti, Monica Morselli, Fabio Forghieri, Monica Maccaferri, Francesco Volzone, Cinzia Del Giovane, Roberto D'Amico, Franco Locatelli, Giuseppe Torelli, Patrizia Comoli, Leonardo Potenza

Blood (2010) 115 (8): 1512–1518.

https://doi.org/10.1182/blood-2009-06-230391

Published: 2010

Journal Articles

Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles

Giovanni Emilia, Mario Luppi, Patrizia Zucchini, Monica Morselli, Leonardo Potenza, Fabio Forghieri, Francesco Volzone, Gordana Jovic, Giovanna Leonardi, Amedea Donelli, Giuseppe Torelli

Blood (2007) 110 (12): 3833–3841.

https://doi.org/10.1182/blood-2006-12-063222

Published: 2007

NARROW

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph + acute lymphoblastic leukemia during long-term imatinib mesylate treatment

Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only